Li GuangZhi, Zhang Dongmei
Department of Basic Medical, Jiangsu College of Nursing, JiangSu, 223005, China.
Open Med (Wars). 2025 Mar 17;20(1):20241124. doi: 10.1515/med-2024-1124. eCollection 2025.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and β-cell dysfunction. A hallmark of T2DM pathology is the accumulation of toxic amyloid polypeptides in and around pancreatic islet cells, leading to the progressive loss of β-cell populations. Human islet amyloid polypeptide (hIAPP), also known as amylin, is a 37-amino acid peptide hormone primarily produced by pancreatic β-cells. hIAPP aggregation and amyloid formation are strongly correlated with β-cell death and disease severity in T2DM patients.
This article aims to review the current research progress on the correlation between hIAPP and T2DM, focusing on the molecular mechanisms and potential therapeutic strategies.
We conducted a comprehensive literature review covering recent studies on the molecular structure, physiological function, and pathological mechanisms of hIAPP. Key areas include biosynthesis, monomer structure, and the formation of hIAPP fiber structures. Additionally, we examined the mechanisms of hIAPP-induced β-cell death, including oxidative stress (OS), endoplasmic reticulum stress (ERS), impaired cell membrane and mitochondrial functions, and inflammatory factors.
Our review highlights the critical role of hIAPP in the pathogenesis of T2DM. Specifically, we found that hIAPP biosynthesis and monomer structure contribute to its physiological functions, while hIAPP aggregation forms toxic amyloid fibers, contributing to β-cell dysfunction. OS, ERS, impaired cell membrane and mitochondrial functions, and inflammatory factors play significant roles in hIAPP-induced β-cell death. There is a strong correlation between hIAPP aggregation and the severity of T2DM, and potential therapeutic approaches using small molecule inhibitors to prevent hIAPP aggregation and fibrosis are discussed.
Understanding the molecular mechanisms of hIAPP in T2DM provides insights into potential therapeutic targets and preventive strategies. Future research should focus on developing more effective treatments targeting hIAPP aggregation and its downstream effects.
2型糖尿病(T2DM)是一种以胰岛素抵抗和β细胞功能障碍为特征的慢性代谢性疾病。T2DM病理的一个标志是胰岛细胞内和周围有毒性淀粉样多肽的积累,导致β细胞群逐渐丧失。人胰岛淀粉样多肽(hIAPP),也称为胰淀素,是一种主要由胰腺β细胞产生的37个氨基酸的肽激素。hIAPP聚集和淀粉样蛋白形成与T2DM患者的β细胞死亡和疾病严重程度密切相关。
本文旨在综述hIAPP与T2DM相关性的当前研究进展,重点关注分子机制和潜在治疗策略。
我们进行了全面的文献综述,涵盖了最近关于hIAPP分子结构、生理功能和病理机制的研究。关键领域包括生物合成、单体结构以及hIAPP纤维结构的形成。此外,我们研究了hIAPP诱导β细胞死亡的机制,包括氧化应激(OS)、内质网应激(ERS)、细胞膜和线粒体功能受损以及炎症因子。
我们的综述强调了hIAPP在T2DM发病机制中的关键作用。具体而言,我们发现hIAPP生物合成和单体结构有助于其生理功能,而hIAPP聚集形成有毒性的淀粉样纤维,导致β细胞功能障碍。OS、ERS、细胞膜和线粒体功能受损以及炎症因子在hIAPP诱导的β细胞死亡中起重要作用。hIAPP聚集与T2DM严重程度之间存在很强的相关性,并讨论了使用小分子抑制剂预防hIAPP聚集和纤维化的潜在治疗方法。
了解hIAPP在T2DM中的分子机制有助于深入了解潜在的治疗靶点和预防策略。未来的研究应侧重于开发针对hIAPP聚集及其下游效应的更有效治疗方法。